Literature DB >> 3296159

Low-dose heparin in the treatment of calcaneal peritendinitis.

A I Larsen, M Egfjord, H M Jelsdorff.   

Abstract

A double-blind, controlled study is presented on the effect of low-dosage heparin on acute calcaneal peritendinitis crepitans in young men. Treatment consisted in exemption from physical work and subcutaneous injection of heparin. 5000 I.U., or placebo, once a day for 5 consecutive weekdays. During the first week the mean total symptom score showed a gradual fall to 32 and 34% of the baseline values in the heparin (n = 10) and the placebo group (n = 10), respectively. On day 15 the value was unchanged in the heparin group, whereas it had increased again to 45% in the placebo group. However, the symptoms and signs recorded never differed significantly between the two groups. No adverse reactions were observed. Consequently, further studies are needed to show whether a treatment of acute peritendinitis can be obtained with heparin in a dosage with less risk of bleeding than that involved in the previously reported regimen.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3296159

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  4 in total

Review 1.  Treatment of midportion Achilles tendinopathy: an evidence-based overview.

Authors:  Ruben Zwiers; Johannes I Wiegerinck; C Niek van Dijk
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2014-11-01       Impact factor: 4.342

2.  Achilles tendon lesions in sport.

Authors:  J G Williams
Journal:  Sports Med       Date:  1993-09       Impact factor: 11.136

Review 3.  Achilles tendon injuries in athletes.

Authors:  M Kvist
Journal:  Sports Med       Date:  1994-09       Impact factor: 11.136

4.  Surgical treatment for chronic Achilles tendinopathy: a prospective seven month follow up study.

Authors:  Mika Paavola; P Kannus; S Orava; M Pasanen; M Järvinen
Journal:  Br J Sports Med       Date:  2002-06       Impact factor: 13.800

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.